Fundraising Fox
Aclipse Therapeutics
Radnor, US · Founded 2017 · Delaware LLC
Find your way into Aclipse Therapeutics
Sign up to see every warm intro you have to Aclipse Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Aclipse Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Aclipse Therapeutics is a clinical-stage biopharmaceutical company developing disease-modifying drug candidates for life-threatening neuromuscular and severe diseases, using genomic, proteomic, and biomarker data. Its lead programs include M107 for gastroparesis and M102 for amyotrophic lateral sclerosis (ALS).
Founders & leadership
RK
Raymond K HouckNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$2.6M disclosed across 5 rounds · 2018–2020
▶$115KraisedAug 2020 · 1 investors · PharmaceuticalsRule 506(b)
▶$115KraisedAug 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Raymond K HouckExecutive Officer, Director
- Amount sold
- $115K
- First sale
- Aug 2020
- Incorporated
- Limited Liability Company, Delaware, 2017
- Federal exemptions
- 06b
▶$25KraisedMar 2020 · 1 investors · PharmaceuticalsRule 506(b)
▶$25KraisedMar 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Raymond K HouckExecutive Officer, Director
- Amount sold
- $25K
- First sale
- Mar 2020
- Incorporated
- Limited Liability Company, Delaware, 2017
- Federal exemptions
- 06b
▶$200KraisedJun 2019 · 1 investors · PharmaceuticalsRule 506(b)
▶$200KraisedJun 2019 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Raymond K HouckExecutive Officer, Director
- Amount sold
- $200K
- First sale
- Jun 2019
- Incorporated
- Limited Liability Company, Delaware, 2017
- Federal exemptions
- 06b
▶$1.2MraisedMar 2019 · 4 investors · PharmaceuticalsRule 506(b)
▶$1.2MraisedMar 2019 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Raymond K HouckExecutive Officer, Director
- Amount sold
- $1.2M
- First sale
- Jan 2018
- Incorporated
- Limited Liability Company, Delaware, 2017
- Federal exemptions
- 06b
▶$1.1MraisedMar 2019 · 3 investors · PharmaceuticalsRule 506(b)
▶$1.1MraisedMar 2019 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Raymond K HouckExecutive Officer, Director
- Amount sold
- $1.1M
- First sale
- Mar 2019
- Incorporated
- Limited Liability Company, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies working in the same space as Aclipse Therapeutics.
In the news
Frequently asked questions
- What does Aclipse Therapeutics do?
- Aclipse Therapeutics is a clinical-stage biopharmaceutical company developing disease-modifying drug candidates for life-threatening neuromuscular and severe diseases, using genomic, proteomic, and biomarker data. Its lead programs include M107 for gastroparesis and M102 for amyotrophic lateral sclerosis (ALS).
- How much funding has Aclipse Therapeutics raised?
- Aclipse Therapeutics has disclosed $2.6M raised across 5 rounds.
- Where is Aclipse Therapeutics headquartered?
- Aclipse Therapeutics is headquartered in Radnor, US.